Drug intelligence / Profile preview

Cas9d

Development stage
Unknown
Lead developer
Metagenomi
Modality
CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Recombinant Proteins and Enzymes, Gene Silencing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration
Intravenous, Intratumoral, Subcutaneous, Intraperitoneal, Intramuscular, Intradermal, Intrastemal, Infusion, Electroporation, Microinjection
01

Overview

Cas9d is a compact, Type II-D CRISPR-associated protein 9 (Cas9) ortholog derived from *Deltaproteobacteria*. Comprising only 747 amino acids, it is recognized as the smallest known member of the Cas9 family, a feature that facilitates efficient delivery via a single adeno-associated virus (AAV) vector due to its small genetic footprint (expression cassette <3.4 kb). Functionally, Cas9d acts as an RNA-guided endonuclease that targets and cleaves double-stranded DNA at sites adjacent to an NGG protospacer-adjacent motif (PAM). It utilizes a unique RNA-coordinated structural module for DNA targeting and exhibits significantly higher fidelity than the widely used *Streptococcus pyogenes* Cas9 (SpyCas9) by demonstrating lower tolerance for base mismatches. While primarily a research tool and platform technology for genome editing and base editing, its compact size and high precision make it a promising candidate for *in vivo* therapeutic applications.

Other names
Type II-D Cas9 orthologDeltaproteobacteria Cas9
02

Targets

DNA

Beyond the preview

Go deeper on Cas9d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cas9d.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call